US Patent

US10010507 — Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor

Formulation · Assigned to Pharmacyclics LLC · Expires 2036-03-03 · 10y remaining

Vulnerability score 25/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects pharmaceutical formulations of a specific Bruton's tyrosine kinase inhibitor, also known as Imbruvica.

USPTO Abstract

Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Drugs covered by this patent

Patent Metadata

Patent number
US10010507
Jurisdiction
US
Classification
Formulation
Expires
2036-03-03
Drug substance claim
No
Drug product claim
Yes
Assignee
Pharmacyclics LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.